A range of therapies now exists to reduce the risk of kidney failure and cardiovascular events in people with type 2 diabetes, including renin-angiotensin system blockade, sodium-glucose cotransporter 2 (SGLT2) inhibitors, non-steroidal mineralocorticoid receptor antagonists, and glucagon-like pepti …
Whether the large effect size of endovascular thrombectomy (EVT) for stroke due to large-vessel occlusion applies to stroke due to medium-vessel occlusion is unclear. In…
AJKD invites applications for its Editorial Internship Program, which will provide editorial experience to early career researchers interested in education, teaching, or medical editing/writing. AJ…
The field of chronic total occlusion (CTO) percutaneous coronary intervention (PCI) has witnessed a dramatic evolution in the last decade. The challenging nature of CTO…
ng of the circulating proteins associated with secondary cardiovascular events may help to identify novel therapeutic targets. Background Cardiovascular risk models have been developed primarily…
“Highlighting Continued Achievements and Exploring Future Opportunities: Insights From the 2024 ASN Nephrology Fellow Survey” published on 08 Jan 2025 by American Society of Nephrology.
The underrepresentation of the environment domain, regional and local stakeholders in the MBV preparedness and response network underlines the remaining challenge of including all relevant…
This trial was registered on ClinicalTrials.gov in April 2019 with the trial identification number NCT03913481.
Endovascular treatment (EVT) of stroke with large-vessel occlusion is known to be safe and effective. The effect of EVT for occlusion of medium or distal…
Whether the large effect size of endovascular thrombectomy (EVT) for stroke due to large-vessel occlusion applies to stroke due to medium-vessel occlusion is unclear. In…
Since the 1970s, hundreds of randomized trials have examined the effects of psychotherapies for depression, and this number is increasing every year. In this study,…
